Evidence map›Paper›PMID 30675745›Full record

Trial reportWound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society2019

Flaminal® versus Flamazine® in the treatment of partial thickness burns: A randomized controlled trial on clinical effectiveness and scar quality (FLAM study).

Zjir M Rashaan, Pieta Krijnen, Kelly A A Kwa, Cornelis H van der Vlies, Inger B Schipper, Roelf S Breederveld

Open access · bronzeAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Interventions for postburn pruritus.The Cochrane database of systematic reviews · 2024
    Pooled it
  3. Long-term quality of life and cost-effectiveness of treatment of partial thickness burns: A randomized controlled trial comparing enzyme alginogel vs silver sulfadiazine (FLAM study).Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2020
    Trial
  4. Article
  5. Article
  6. Luteolin is an Effective Component ofClinical, cosmetic and investigational dermatology · 2022
    Article
  7. Review
  8. Article
  9. Article
  10. Metal Complexes, an Untapped Source of Antibiotic Potential?Antibiotics (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Zjir M RashaanDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Pieta KrijnenDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Kelly A A KwaDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Cornelis H van der VliesBurn Centre and Department of Surgery, Maasstad Hospital, Rotterdam, The Netherlands.
Inger B SchipperDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Roelf S BreederveldDepartment of Surgery, Leiden University Medical Centre, Leiden, The Netherlands.
Association of Dutch Burn Centres · NLLeiden University Medical Center · NLErasmus MC · NLLeiden University · NL

Funding

Dutch Burns Foundation 12.109
6 · The paper itself

Abstract

Although partial thickness burns are the most frequently reported burn injuries, there is no consensus on the optimal treatment. The objective of this study was to compare the clinical effectiveness and scar quality of Flaminal® Forte to silver sulfadiazine (Flamazine®) in the treatment of partial thickness burns. In this two-arm open label multicenter randomized controlled trial, adult patients with acute partial thickness burns and an affected total body surface area of less than 30% were randomized between Flaminal® Forte and Flamazine® and followed for 12 months. Dressing changes in the Flamazine® group were performed daily, and in the Flaminal® group during the first 3 days post burn and thereafter every other day until complete wound healing or surgery. Forty-one patients were randomly allocated to Flaminal® Forte and 48 patients to Flamazine®. The primary outcome was time to wound healing, which did not differ between the groups: median 18 days with Flaminal® Forte (range 8-49 days) versus 16 days with Flamazine® (range 7-48 days; p = 0.24). Regarding the secondary outcomes during hospital admission, there were no statistically significant differences between the groups concerning need for surgery, pain scores, pruritus, or pain-related and anticipatory anxiety. More patients in the Flaminal® group developed wound colonization (78% versus 32%, p < 0.001), but the treatment groups did not differ regarding the incidence of local infections and use of systemic antibiotics. In terms of scar quality, no statistically significant differences between both treatment groups were found regarding subjective scar assessment (Patient and Observer Scar Assessment Scale (POSAS)), scar melanin and pigmentation (DermaSpectrometer®), and scar elasticity and maximal extension (Cutometer®) during 12 month postburn. In conclusion, time to wound healing did not differ, but the use of Flaminal® Forte seemed favorable because less dressing changes are needed which lowers the burden of wound care.

Indexed as

AdultAgedAlginatesAnti-Infective Agents, LocalBurnsCicatrixDrug CombinationsFemaleGlucose OxidaseHumansLactoperoxidaseMaleMiddle AgedPolyethylene GlycolsRe-EpithelializationSilver SulfadiazineAlginatesAnti-Infective Agents, LocalDrug CombinationsFlaminalGlucose OxidaseLactoperoxidasePolyethylene GlycolsSilver Sulfadiazine

Identifiers

PMID30675745
PMCPMC6850327
OpenAlexW2912207415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.